CN Patent
CN101370792B — 激酶的联-芳基间-嘧啶抑制剂
Assigned to Biomedical Impact Co · Expires 2013-03-20 · 13y expired
What this patent protects
本发明提供了具有一般结构(A)的联芳间-嘧啶化合物。本发明的嘧啶化合物能够抑制激酶,诸如Jak激酶家族中的成员和各种其它特异性受体和非-受体激酶。
USPTO Abstract
本发明提供了具有一般结构(A)的联芳间-嘧啶化合物。本发明的嘧啶化合物能够抑制激酶,诸如Jak激酶家族中的成员和各种其它特异性受体和非-受体激酶。
Drugs covered by this patent
- Inrebic (FEDRATINIB HYDROCHLORIDE) · Bristol-Myers Squibb
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.